INNOVENT BIOLOGICS Aktie

 

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001) Innovent will receive an upfront payment, and is eligible to receive development, regulatory and......

CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) today announced an exclusive license agreement for SP001 (Innovent R&D code: IBI355), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize SP001 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advance SP001 into a Phase 2 study in IgG4-RD patients in Q2 2027; Innovent expects to initiate a Phase 2 trial in China for SjD by early 2027....

Nomura published a report stating that growth in the market for GLP-1 receptor agonists (GLP-1 RAs) in the rest of the world (ROW) will drive significant expansion of the drug category. The global GLP-1 RAs market is currently valued at USD72 billion. According to third-party forecasts, the market size is expected to reach USD18......

BofAS published a research report stating that active licensing transactions in China's pharmaceutical industry, together with companies' continued advancement in R&D innovation, will support a valuation re-rating of the sector.CSPC PHARMA (01093.HK) recently announced a cooperation agreement with AstraZeneca PLC Ordinary Shares......

UBS published a research report stating that it recently invited INNOVENT BIO (01801.HK) to participate in its healthcare virtual roadshow conference. Following strong product sales in 1Q25, management said sales momentum remained solid in 2Q25 and that it had not observed significant sales disruption from anti-corruption activi......

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and......

CMBI issued a research report noting that the MSCI China Healthcare Index has cumulatively declined by 11.4% since the beginning of 2026, outperforming the MSCI China Index by 0.2 ppts. The broker believes the recent pullback in the pharmaceutical sector was mainly affected by liquidity factors, policy factors and geopolitics. H......

SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,......

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOVENT BIO (01801.HK) announced that the international Phase III clinical study (G-HOPE-001, NCT06238843) of IBI343 for patients with advanced gastric cancer has completed its first interim analysis as pre-specified and met the primary endpoint. Based on these positive clinical results, the company has submitted a New Drug App......

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,......

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four The post Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal appeared first on Pharmaceutical Business review....

Pfizer schließt eine der größten Biotech-Kooperationen des Jahres ab und setzt dabei auf chinesische Krebsforschung. Was steckt hinter dem 10,5-Milliarden-Deal mit Innovent Biologics? --- Der Deal fällt in eine Phase, in der sich westliche Pharmakonzerne geradezu auf chinesische Biotech-Pipelines stürzen. Das Volumen solcher Lizenzabkommen aus Greater China hat sich laut dem Datenanbieter Pharmcube zwischen 2021 und dem vergangenen Jahr fast verzehnfacht und erreichte 2024 einen Rekordwert von rund 138 Milliarden US-Dollar..

China's Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday. Innovent, which is based in Suzhou in China's eastern Jiangsu......

Der US-amerikanische Pharma-Riese Pfizer verstärkt seine Entwicklungspipeline. Für bis zu 10,5 Milliarden Dollar sichert sich das Unternehmen die Rechte an zwölf Wirkstoffen der chinesischen Innovent Biologics. Die Aktie der Asiaten gewinnt an der Heimatbörse nach Bekanntwerden des Deals um rund zehn Prozent....

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOVENT BIO (01801.HK) opened 6.88% higher today, hitting an intraday peak of HKD82.4. It last quoted at HKD80.65, up 7.75%, with a turnover of 5.4011 million shares, involving HKD438 million.INNOVENT BIO announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US) for......